QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., reported 2025 financial results, achieving first annual profitability with net profit of RMB 135 million (USD 19.6 million). The company became the first profitable Hong Kong-listed company in the AI for Science (AI4S) sector, with global sales skyrocketing 201.2% YoY to RMB 803 million (USD 116 million). The drug discovery solutions business drove exceptional growth, surging 418.9% to RMB 538 million fueled by antibody business expansion and milestone achievements across partner pipelines.
Financial Highlights
Metric
2025 Result
YoY Change
Sector Significance
Global Sales
RMB 803 million (USD 116M)
+201.2%
Hypergrowth validates AI drug discovery commercial model
Net Profit
RMB 135 million (USD 19.6M)
First profitable year
First HK-listed AI4S profitability – sector milestone
Drug Discovery Solutions
RMB 538 million (USD 78M)
+418.9%
Core engine of growth; antibody business + partner milestones
Profitability supports premium valuation vs. pre-revenue AI biotech peers; potential index inclusion (Hang Seng Tech)
2026 Catalysts: Additional profitability quarters; major pharma partnership announcements; AI model regulatory validation (FDA/EMA engagement on AI-generated INDs)
Competitive Landscape: Positions against Schrödinger (SDGR), Recursion (RXRX), Insilico Medicine; XtalPi’s first profitability + China market depth provides differentiation
Forward‑Looking Statements This brief contains forward‑looking statements regarding sustained profitability, partner pipeline progression, and AI model regulatory acceptance. Actual results may differ due to partner milestone timing, competitive AI platform development, and macroeconomic factors affecting biotech R&D spending.-Fineline Info & Tech
By Fineline Cube 